Related Experiment Video
Updated: Aug 9, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
[Reversible cardiac valve abnormalities with pergolide treatment]
V Calomne1, M J-M Dupuis, T Muller
1Service de Neurologie, Clinique Saint-Pierre, Ottignies, Belgique.
Abstract:
We report the case of a parkinsonian patient treated by pergolide who developed aortic and mitral regurgitations and pulmonary hypertension. When she stopped the medication, the cardiac symptoms disappeared. Retroperitoneal and pleural fibrosis have been described with pergolide but never valvulopathy until 3 cases reported in December 2002.
Insights
Pergolide, a medication for Parkinson's disease, may cause heart valve damage (valvulopathy) and pulmonary hypertension. Stopping the drug resolved these cardiac symptoms in a patient, suggesting a causal link.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Pergolide is a dopamine agonist used to treat Parkinson's disease.
- Fibrotic complications, including retroperitoneal and pleural fibrosis, have been associated with pergolide use.
- Valvulopathy has not been previously reported in association with pergolide.
Observation:
- A patient with Parkinson's disease treated with pergolide developed aortic and mitral regurgitation.
- The patient also presented with pulmonary hypertension.
- Cardiac symptoms resolved after discontinuation of pergolide therapy.
Findings:
- This case report suggests a potential link between pergolide and the development of cardiac valvulopathy.
- The findings indicate that pergolide may induce or exacerbate valvular heart disease and pulmonary hypertension.
- This is one of the first reports linking pergolide to valvulopathy, following three similar cases in late 2002.
Implications:
- Clinicians should be aware of the potential cardiac risks associated with pergolide treatment.
- Monitoring for cardiac valvulopathy and pulmonary hypertension is crucial in patients receiving pergolide.
- Further research is warranted to elucidate the mechanism of pergolide-induced valvulopathy.
More Related Videos
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Mitral Regurgitation III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Stenosis III: Medical Management
Aortic Regurgitation III: Medical Management
Cardiomyopathy V: Interprofessional Care